Virus crisis costing Swiss economy $11-17 billion per month

People line outside a supermarket during the coronavirus disease (COVID-19) outbreak in Geneva. (Reuters File Photo)
Short Url
Updated 10 May 2020
Follow

Virus crisis costing Swiss economy $11-17 billion per month

  • Switzerland needs to dish out some $100 billion to mitigate the effects of the crisis

GENEVA: Switzerland’s central bank chief said in an interview published by Swiss media Sunday that the coronavirus crisis was costing the Swiss economy up to $17 billion each month.

The head of the Swiss National Bank, Thomas Jordan, said the crisis surrounding the COVID-19 pandemic was weighing heavily on the Swiss economy, which was currently functioning at just 70-80 percent of its normal level.

“You have to go back to the oil crisis of the 1970s to find such a collapse of growth,” he told the Tamedia group in an interview.

The impact of the widespread measures put in place in the Alpine nation to halt the spread of the virus was running up “enormous” costs, he said, “to the tune of 11-17 billion Swiss francs ($11.3-$17.5 billion) each month.”

Jordan cautioned that the public debt would swell, as would costs linked to unemployment insurance and to the subsidies provided to businesses to keep them afloat, pushing Switzerland toward a significant deficit this year.

FASTFACTS

The head of the Swiss National Bank, Thomas Jordan, says the coronavirus crisis is weighing heavily on the Swiss economy.

He cautions that the public debt would swell, as would costs linked to unemployment insurance and to the subsidies provided to businesses to keep them afloat.

The Le Matin Dimanche and SonntagsZeitung weeklies calculated Sunday that Switzerland in all should dish out some 100 billion to mitigate the effects of the crisis.

They pointed out that in April joblessness surged 43 percent compared to the same month in 2019 with some 2 million people, out of a population of 8.5 million, drawing partial unemployment benefits. Switzerland has stopped short of ordering full confinement, but introduced a range of emergency measures in mid-March, including closing restaurants and most other businesses, to combat the spread of the novel coronavirus.

The wealthy Alpine nation has gradually begun lifting measures, with restaurants, shops and schools due to open Monday.

Jordan said the loosening of confinement measures was vital, stressing the need to step up economic activity to keep a handle on the rising debt levels.

“It makes sense that the gradual deconfinement should start now,” he said, insisting that Switzerland’s essential education, health and retirement systems “rest on the stability of our economy.”

Jordan said the central bank had been busy intervening in foreign exchange markets to stabilize the value of the Swiss franc which is considered a refuge currency in times of crisis.


Saudi-French cooperation to localize veterinary vaccine manufacturing

Updated 16 sec ago
Follow

Saudi-French cooperation to localize veterinary vaccine manufacturing

RIYADH: In the presence of sector leaders, the National Livestock and Fisheries Development Program signed a memorandum of understanding with French company Ceva under the patronage of Minister of Environment, Water and Agriculture Abdulrahman bin Abdulmohsen Al-Fadhli, who also chairs the program’s board.

The agreement aims to localize vaccine manufacturing, transfer technology and technical expertise, and expand the industrial and commercial production of veterinary vaccines across the Kingdom.

According to the MoU, the two parties will work to achieve high efficiency in mass production scale-up and establish a clear path for sustainable commercial operation that meets the needs of the local and national market, as well as strengthen the biosecurity and food security system.

The MoU also includes the development and modernization of messenger RNA vaccine technologies, along with joint research and development of a Middle East Respiratory Syndrome vaccine for camels. This involves designing, evaluating, and developing vaccines specifically tailored to combat the virus.

The agreement also covers the development of a rabies vaccine and related solutions, as well as supporting national efforts to control the disease through vaccine provision, capacity building, and the implementation of integrated prevention strategies.

The collaboration between the program and Ceva aims to meet the needs of the poultry vaccine market in the Kingdom, currently estimated at around SR750 million ($199 million).

The company will work to cover approximately 30 percent of this market with an initial investment of around SR250 million.

With continued government support for poultry projects and increased production in the sector, the market is expected to grow at a rate exceeding 10 percent annually, reaching approximately SR1.25 billion by 2030.

The addition of the world’s leading poultry vaccine manufacturer to Biotech Park highlights the program’s key role in developing new industries within the livestock and fisheries sector.

It also highlights the program’s commitment to building international partnerships with global companies, organizations, research centers, and universities to support advanced biotechnology industries and attract high-quality investments. It also seeks to create new economic sectors based on biotechnology, enhance veterinary health security, and support the sustainable economic development of the livestock sector, as well as empower national and emerging companies and provide advanced research and industrial infrastructure.

This will solidify the Kingdom’s position as a global hub for biotechnology industries and the development of national capabilities.

Ceva is the first international partner to join Biotech Park, the future veterinary biotechnology city launched by the program in Dhurma Governorate. The city is the world’s first specialized and fully integrated hub for veterinary biotechnology, serving as a benchmark for sector development and a platform supporting markets across the Kingdom, the Gulf, the Middle East, Africa and beyond.

The signing of Ceva is a significant step, given its position as the world’s leading manufacturer of poultry vaccines and medicines, and one of the most prominent international companies in the field of biotechnology.

The MoU aims to localize the veterinary vaccine industry, ensuring its compatibility with the strains of poultry diseases prevalent in Saudi Arabia. This includes the transfer of technology and technical expertise from Ceva, along with the implementation of specialized training programs to guarantee that manufacturing facilities comply with international Good Manufacturing Practice standards.